Skip to content
Screener

Palvella Therapeutics PVLA Q4 2025 Annual earnings

Reported March 31, 2026 · Before market open

EPS-$1.08Miss by $0.17
EPS estimate-$0.91

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$16.7K
EPS estimate-$1.74

Financials

Q4 2025

Income statement

See full
Operating income-$11.3M-159%
Net income-$12.7M-222%
EPS (diluted)-$1.08—

Balance sheet

See full
Cash & equivalents$58.0M-30.6%
Total debt$633.0K—
Total equity$28.0M-55.3%
Total assets$59.6M-32.5%

Cash flow

See full
Operating cash flow-$4.9M+8.7%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.24B+820%
Enterprise value$1.18B—

Returns & leverage

See full
Return on equity-92.1%—
Debt / equity0×—
Current ratio5.2×-2.1×

FAQ

When did Palvella Therapeutics report Q4 2025 earnings?
Palvella Therapeutics (PVLA) reported Q4 2025 earnings on March 31, 2026 before market open.
What were Palvella Therapeutics's Q4 2025 revenue and EPS?
Palvella Therapeutics reported eps of $-1.08 for Q4 2025.
Did Palvella Therapeutics beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.91 by $0.17.
Where can I find Palvella Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-133332) and the 10-K periodic report (0001193125-26-133372) directly on SEC EDGAR. The filing index links above go to sec.gov.